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ABSTRACT 
BACKGROUND AND OBJECTIVES: 
Stroke is the third commonest cause of death worldwide, after coronary 
heart disease (CHD) and all types of cancer. Fibrinogen is an independent risk 
factor for stroke and also predictor of future recurrences of stroke. Hence, 
Measurement of fibrinogen levels could be more useful than others as it  is more 
specific to vascular disease. The objective of this study is to test the hypothesis 
that increased fibrinogen in ischemic stroke is related with severe onset and  
poor prognosis.  
 
METHODS: 
Patients admitted with history of acute onset of stroke in Department of 
Medicine within 48 hours of onset of stroke were enrolled in after excluding the 
exclusion criteria. Age and sex matched persons not having focal neurologic 
deficit and after verifying exclusion criteria were taken as controls. The study 
was done in 100 subjects ,50 cases and 50 controls. Fibrinogen was measured 
quantitatively by Clauss method. Severity was assessed using National Institute 
of Health Sciences Stroke Scale at admission. Reassessment of morbidity and 
mortality using Modified Rankin’s scale scores at one month follow-up. 
 
RESULTS: 
The mean fibrinogen level among cases was 612.20 and controls was 
296.80, with a p value of 0.001 (< 0.05. In the study, the mean fibrinogen levels 
are higher in cases than controls irrespective of presence or absence of other 
risk factors,which was statistically significant(p<0.05). It was clear from the 
study that the acute ischemic stroke was very severe in patients with higher 
fibrinogen levels. Also, the outcome at the end of one month was poor in 
patients with higher fibrinogen levels during stroke onset. 
KEY WORDS: Fibrinogen, Acute Ischemic stroke. 
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     INTRODUCTION 
Fibrinogen plays a key role in blood clotting. Its association with 
increased incidence of stroke is related to its ability to promote thrombosis or 
clot formation by causing platelets to clump inside blood vessels. It also 
interacts with monocytes/macrophages which are thought to play a important 
role in atherogenesis. This interaction also triggers the procoagulant activities. 
Normal serum Fibrinogen level is 233 to 496 mg/dl. Fibrinogen bridges 
adjacent platelets together to form platelet aggregates and results in arterial 
thrombosis leading to ischemic stroke.
1
 
 It is an independent type of  risk factor for recurrences of stroke apart 
from age, smoking, hypertension, diabetes and other risk factors. It is also a 
predictor of future recurrences of stroke and adverse cardiovascular events. 
Hence, fibrinogen levels are to be measured in patients with stroke at the 
earliest and to be treated.
1
 
Fibrinogen plays significant role in a number of physiological and 
pathological processes like inflammation and atherogenesis and 
thrombogenesis. This is due to infiltration of blood vessel wall by fibrinogen, 
increase in blood viscosity and its, haemorrheological effects, increased 
aggregation of platelets and subsequent thrombus formation. The binding of 
fibrinogen to ICAM-1 receptors on vascular endothelium mediate the platelet 
adhesion. Fibrinogen causes damage of endothelium and its dysfunction by a 
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variety of mechanisms. This is supported by the decrease in intimal fibrinolytic 
activity and plasminogen level observed in cardiovascular disease. Fibrinogen 
plays a role in the process of aggregation of platelets. It crosslinks the platelets 
by the process of binding the glycoprotein IIb-IIIa receptor on the surface of 
platelets. This is more relevant with the adventure of glycoprotein IIb-IIIa 
receptor inhibitors. Hence, Measurement of plasma fibrinogen levels could be 
more useful than other acute phase reactants such as C-reactive protein, as 
fibrinogen is more specific to vascular disease. The primary objective of this 
study dissertation is to test the hypothesis that increased fibrinogen in ischemic 
stroke is related with poor prognosis. Besides, the dissertation also identifies the 
association of fibrinogen with other multiple variables like age, sex, body 
weight, smoking, cholesterol, hypertension and diabetes.
2
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REVIEW OF LITERATURE 
FIBRINOGEN: 
STRUCTURE OF FIBRINOGEN: 
Fibrinogen is a glycoprotein soluble in nature, synthesised predominantly 
in liver and secreted into plasma. It is about 45 nm long and 9 nm in diameter 
with a molecular mass of about 340 kilo Dalton. 
Fibrinogen molecule is a large tri-nodular glycoprotein with two 
symmetrical half molecules. One half contains three polypeptide chains (A α, B 
β, gamma) linked to by disulphide bonds. The NH-2 terminal of all six 
polypeptide chains form NH-2 terminal disulphide knot, which lies in the 
central nodule or E- domain which is 5 nm in diameter. The c-terminal two 
thirds of both B β and gamma chains lie in the outer two D- domain nodules. 
Between E- and D- domains ,a stretch of about 120 amino acids from each of 
the three chains form an ‘coiled coil domain’ ,which is an α helical structure. 
This region is supported by disulphide rings on both sides. This disulphide rings 
make fibrin mechanically strong and resistant to proteolysis.
3
 
The A α polypeptide chain is divided into three distinct domains and 
contain 610 amino acids. The first section of A α chain (residue 1- 194) contains 
a region (residues 45-161) which by disulphide bonds is linked to B β and 
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gamma chains. It also forms part of α helix or coiled coil domain. It also contain 
fibrinopeptide A and the polymerisation site in the E domain. 
The middle section of A α chain (240 – 424 residue) is rich in apolar 
aminoacids. It contains ten tandem repeats each of thirteen aminoacids long. 
The bridging regions of first two sections contain a protease sensitive domain 
having high content of pralines and several plasmin cleavage sites. There are 
two glutamine residues in middle section of  A α chain which serve as cross 
linking receptor sites for factor XIII a. 
The third section is the hydrophilic C- terminal of the molecule (residue 
425- 610). It contain the cross linking sites for fibronectin and α -2 anti plasmin. 
There are two (arginine,glycine, aspartic acid ) sequences in A α  chain that play 
a role in cellular adhesion events.
3
 
The B β polypeptide chain contains 461 aminoacids which is also divided 
into three sections. The first 80 residues form first section which contains 
fibrinopeptide B sequence ( residue 1-15 ) and a site that support endothelial 
cell spreading and proliferation ( residue 16 – 42). The middle section (residues 
81 – 192) forms part of coiled coil domain and is linked by disulphide bonds to 
A α and gamma chains. The C terminus forms one of the independently folded 
subdomain of D domain. 
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The gamma chain is 411 aminoacid long and is divided into three section. 
The first 18 aminoacids form part of NH-2 terminal disulphide knot. The middle 
section contain aminoacids 19- 135 and contain disulphide rings which link this 
region to the A α and Bβ chains in the coiled coil domain. The C terminal 
section contain aminoacids 136 – 411 and form globular subdomain of the D 
domain. In this region, there is D domain polymerisation site, factor XIII a cross 
linking site and binding domain for platelet aggregation. 
In human, the plasma fibrinogen has two distinct forms of gamma chain. 
The gamma
1 
chains constitute 15% and contain an extended C- terminal. It is 
produced by alternative polyadenylation of the last intron of gamma chain gene.  
The B β and gamma chains contain asparagine residue which serve as N-
glycosidic linkage for carbohydrate attachment. In diseases with hepatic injury, 
a fetal form of fibrinogen is produced which has more sialic acid attached to 
carbohydrate side chain. It results in defective polymerisation of fibrins and also 
associated with cirrhosis and hepatomas. This defective polymerisation in fetal 
fibrinogen does not cause bleeding but can produce significant prolongation of 
clotting time in in-vitro assays.
3
 
SYNTHESIS OF FIBRINOGEN: 
Fibrinogen is exclusively synthesised in liver by hepatocytes. Three  
genes located separately on chromosome-4 (Ch4q23-q32) under coordinated 
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control synthesize the three chains. This is followed by subsequent assembly of 
these chains and carbohydrate side chain attachment, after which the mature 
molecule is secreted into circulation. The half life is 72- 108 hrs (average 100 
hr) and the catabolic rate is 25% per day. The fibrinogen turnover rate is 1.7 to 5 
gram per day or 30 – 60 mg per kilogram per day.4 
FUNCTIONS OF FIBRINOGEN: 
Fibrinogen plays an important role in three major processes which are as 
follows:  
1) During blood coagulation process, soluble fibrinogen is converted into  
insoluble fibrin. 
2) The polymerised fibrin acts as a template and activates fibrinolytic 
system, which modulates fibrin deposition and clot dissolution. 
3)  Fibrinogen binds to Gp IIb/IIIa receptor on platelets and cause platelet 
aggregation and also to endothelial cells where it participate in tissue 
repair. 
There are three distinct phases in conversion of fibrinogen to fibrin which is 
insoluble. They are: 
a) Thrombin mediated enzymatic cleavage of fibrinopeptide. 
b) Polymerization of fibrin. 
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c) Stabilisation of fibrin through covalent cross linking which is mediated  
by factor XIIIa. 
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In the first phase, there will be cleavage of  A α chain and of B β chain by 
thrombin leading to release of two molecules of fibrinopeptide A and two 
fibrinopeptide B per molecule of fibrinogen.This results in fibrin monomer 
formation. The constituent chains of fibrin monomer are now termed as α-, β- 
and gamma-chain.
3,4
  
The next phase involves reciprocal non covalent interaction of molecular 
determinants in the E region of the molecule which are exposed after removal of 
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FPA, with complementary binding site located in D region of an adjacent fibrin 
monomer. This results in dimer that is arranged in a half-staggered overlap. The 
dimer continues to grow in length by addition of fibrin monomers. The result of 
which is formation of a two stranded half-staggered polymer termed as 
protofibril. The protofibril is the basic structural unit of fibrin clot.  
The two D domains of longitudinally aligned fibrin molecules in each 
row of protofibril come into close contact with one another by the process of 
half staggered polymerization.This results in further stabilisation of non- 
covalently associated fibrin protofibril. The process of polymerisation continues 
with formation of long double stranded protofibrils that ultimately associate 
laterally to form thick fibrin bundles.  
The FPB cleavage occur during initial phase of polymerisation and 
expose the determinant which are complementary with binding sites located in 
C- terminal of α chain. This step increases the rate of formation of thin fibrils 
and the lateral aggregation to form thick fibrin fibers. 
The formation of covalent amide bonds between the ϵ- amino group of 
specific lysine residues and gamma- CONH2 groups of certain glutamine 
residues through factor XIIIa mediation is characteristic of final stage of fibrin 
formation.  
10 
 
The dimerization of gamma chain is then followed by progressive 
covalent linking of multiple α chains. The net result of covalent stabilisation is 
that the clot becomes more compact and resistant to mechanical disruption and 
dissolution by plasmin.
3,4
 
FIBRINOGEN MEASUREMENT: 
  There are variety of tests for fibrinogen that can been used by 
laboratories. Some tests are used for emergency situations where an estimate of 
whether  normal or grossly decreased levels can be made out.
5
 
 
TYPES OF FIBRINOGEN ASSAY: 
THE CLAUSS ASSAY (CLOTTING RATE ASSAY): 
In this type of assays, thrombin (from 35 to 200 U ⁄ ml) is added to dilute 
the plasma and the clotting time is measured. The result is compared with a 
curve, prepared by clotting a series of dilutions of a reference plasma sample, 
the fibrinogen concentration of which is known and the result in g ⁄ l is obtained. 
This technique is relatively time consuming. The end-point depends on tensile 
strength of the clot and this makes them sensitive at low fibrinogen levels. They 
are affected by heparin therapy. 
  Photo-optical systems depend on change in optical density 
resulting due to fibrin formation.
5,6
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PROTHROMBIN TIME DERIVED TESTS(PT-Fg): 
The estimation of Fibrinogen derived from the prothrombin time (PT-Fg) 
have been widely used in recent years. The analyser is calibrated by performing  
prothrombin time on a plasma (or series of dilutions of plasma) with  known 
fibrinogen concentration and then by plotting a graph of optical change against 
the fibrinogen concentration. The resulting optical change in each test sample is 
then converted to a fibrinogen value.
5,6
 
 
CLOTTABLE PROTEIN ASSAY: 
These type of assays are very accurate and have been used as reference 
assays for fibrinogen. In this assay, Thrombin is added to plasma in the absence 
of calcium ions and the clot is washed. It is then dissolved in alkaline urea or 
other reagents, followed by spectrophotometric protein assay or estimation.
5,6 
 
IMMUNOLOGICAL ASSAY:  
There are number of immunological assays are available namely, enzyme 
linked immunosorbent assays (ELISAs), radial immunodiffusion and 
electrophoretic techniques.
5,6 
 
FIBRINOGEN TITRE: 
It is an emergency test where plasma is diluted in different types of buffer 
before the addition of thrombin. The resultant titre is reported as the last dilution 
12 
 
to display a clot after a given incubation time. This test can be performed inspite 
of the presence of various inhibitors The results are inaccurate and it is time 
consuming and also does not lend itself to automation.
5,6
 
 
GRAVIMETRIC ASSAYS: 
  In this assays, fibrinogen is clotted from the dilute plasma by using a 
strong thrombin solution and calcium chloride. The clot thus formed is 
compressed to express solution and non-clotted proteins which is then washed 
in saline, and dried and weighed on an accurate microbalance.  
 
SULPHITE PRECIPITATION TECHNIQUES: 
This techniques have been described by Rampling & Gaffney in 1976  
but are unreliable in some clinical situations (like in patients with acute phase 
reaction). They are not normally used in hospital haematology laboratories.
5,6
 
 
PRE-TEST VARIABLES: 
 The WHO recommended anticoagulant for fibrinogen assay is tri-sodium 
citrate in a strength of 0.105–0.109 mol ⁄ l, (1 part anticoagulant: 9 parts blood), 
such as used for other blood coagulation tests. The inadequate filling of 
the collection tube affects this ratio which leads to inaccurate results. For 
haematocrit values greater than 0.55 l ⁄ l, the final blood citrate concentration 
requires an adjustment and there are charts available which indicate the amounts 
13 
 
of anticoagulant and blood that are to be mixed. Samples with any clots or 
marked haemolysis should be rejected.
7
 
 
REGIONAL VARIATIONS IN PLASMA FIBRINOGEN LEVELS: 
Several studies showed that that the normal plasma fibrinogen level 
ranges from 2.3 to 4.0 gram / dl. This is strongly influenced by method of 
measurement. The regional variations found in fibrinogen levels are as a result 
of undefined environmental factors and are not related to patient 
characteristics.
7,8
 
 
FIBRINOGEN ABNORMALITIES: 
The fibrinogen abnormalities can be either congenital or acquired. In both 
cases there may be a qualitative or quantitative abnormality in fibrinogen. In 
certain cases both abnormalities can be present in the same patient. 
a) CONGENITAL DISORDERS: 
i) CONGENITAL AFIBRINOGENEMIA: 
It is inherited as autosomal recessive disorder with both 
parents acting as carriers. Usually the fibrinogen level is less than 
0.1 gram per litre of plasma. It manifests as umbilical cord 
bleeding, cutaneous bleeding, gastrointestinal haemorrhage, 
intracranial bleed (rarely) and intra-articular bleed. The laboratory 
evaluation shows prolongation of PT, a PTT and thrombin time 
14 
 
with zero or trace plasma fibrinogen levels. It can be treated by 
transfusion of cryoprecipitate or fibrinogen concentrates and anti 
fibrinolytic agents.
6,7
 
 
ii) CONGENITAL HYPOFIBRINOGENEMIA: 
It is inherited as an autosomal dominant or autosomal recessive 
disorder. The plasma fibrinogen level is between 0.1 gram per litre 
and lower limit of normal reference range for that laboratory. The 
clinical manifestations include umbilical cord bleeding, cutaneous 
bleeding, gastrointestinal haemorrhage, intracranial bleed (rarely) 
and intra-articular bleed. The investigations will show normal 
aPTT, prolonged PT and mildly prolonged TT. They are treated 
with cryoprecipitate or fibrinogen concentrates and anti fibrinolytic 
agents.
6,7
 
iii) CONGENITAL DYSFIBRINOGENEMIA: 
It is inherited as autosomal dominant or recessive disorder. This is 
characterised by synthesis of abnormal fibrinogen molecule which 
exhibits altered functional properties and altered thrombin 
mediated conversion to fibrin. It usually manifests as thrombosis 
and there will be no evidence of hemorrhage. The investigations 
will show normal aPTT and PT. There will be increased thrombin 
time and reltiplase time. The fibrin assay is normal. There will be 
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higher fibrinogen for immunogenic than thrombin clotting method. 
They are treated with cryoprecipitate or fibrinogen concentrates 
with anticoagulants for thrombosis.
6,7,8
 
b) ACQUIRED DISORDERS7,8: 
i)HYPOFIBRINOGENEMIA: 
 It occurs as a result of one of the following causes: 
a) Decreased biosynthesis of fibrinogen by hepatocyte due to 
decompensated liver disease and fulminant hepatic failure. 
b) Disseminated intravascular coagulation due to increased 
consumption. 
c) Drugs like valproic acid and L-Asparaginase 
d) Alcohol consumption- it decreases fibrinogen level by 0.78% 
for each 10 gram of alcohol consumed. 
e) Fibrinolytic therapy will reduce fibrinogen level for one or two 
days. 
ii) DYSFIBRINOGENEMIA: 
 It can be due to: 
a) Idiopathic. 
b) Liver disease- 50% of patients with cirrhosis, hepatitis and 
hepatomas show functional abnormality in fibrin 
polymerization. 
c) Multiple myeloma - Abnormal fibrin monomer polymerization. 
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d) Paraneoplastic syndrome in association with hypernephroma. 
e) Autoimmunity – antibody mediated functional abnormality in 
SLE, Ulcerative colitis and post- necrotic cirrhosis. 
iii)HYPERFIBRINOGENEMIA: 
1) Age : 
 As age advances there will be increase in fibrinogen 
level.
9,10
 
2) Sex : 
 It is more in males compared to females.
9
 
3)  Race : 
 Fibrinogen levels are more in blacks than whites.
9
 
4) Smoking : 
 It is has a positive correlation with plasma fibrinogen level.
9
 
The high fibrinogen level in heavy smokers is usually due to: 
- Endothelial injury by leading to activation of coagulation 
system.
11
 
- Release of interleukin-6 by lung macrophages which  
increase the hepatocyte fibrinogen synthesis.
12
 
5) Physical activity:  
The fibrinogen concentration is inversely proportional to 
physical activity.
12,13  
 
6) Diet : 
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Increased carbohydrate and fat, decreased ω-3 and ω-6 
PUFA’s and fibre increase fibrinogen level. 
7) Obesity :  
Obesity results in increased viscosity and fibrinogen levels. 
8) Hyperlipidemia : 
High cholesterol, LDL, Lp(a) and elevated triglycerides are 
associated with high fibrinogen levels which in turn consistent 
with increased thrombotic complications in dyslipidemias. 
9) Hypertension :  
Fibrinogen levels are more in hypertensives than 
normotensive persons. 
10)Diabetes mellitus: 
 There is positive correlation between serum fibrinogen, 
hyperglycemia and increased glycated haemoglobin. Hence it will 
be more in diabetics than non – diabetic individuals. 
11) Ischemic heart disease: 
 There is a positive correlation with fibrinogen level and 
severity of coronary artery disease. 
12) Left ventricular dysfunction: 
The increased fibrinogen level seen in left ventricular dysfunction  
is responsible for intra cardiac thrombus and systemic 
thromboembolism.
14
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13)  Atrial fibrillation: increased in chronic atrial fibrillation. 
14) Psychological and mental stress increases fibrinogen level. 
15) Cerebrovascular disease: 
 Increased fibrinogen level is associated with stroke, TIA 
incidence and carotid atherosclerotic progression and peripheral 
vascular disease. 
16) Social class: 
 Fibrinogen levels are higher in low socioeconomic class 
individuals. 
17) Family history of IHD. 
18) Dental disease: Chronic inflammatory gingival and 
periodontal infections. 
19) Elevated leukocyte counts:  
20) Acute inflammation and infections:  
As an acute phase reactant fibrinogen is elevated by three 
fold in acute inflammation and infections. 
21) Genetics: 
 The plasma fibrinogen formation is significantly influenced 
by genetics. Variation occurring in β fibrinogen locus affects 
fibrinogen concentration. The β gene controls the formation of Bβ 
chain, the rate limiting step in synthesis of fibrinogen.
15
  
 
19 
 
STROKE 
DEFINITION: 
 
Stroke is defined by WHO as ‘rapidly developing clinical signs of focal 
(or global) disturbance of cerebral function, with symptoms lasting 24 h or 
longer, or leading to death, with no apparent cause other than of vascular 
origin’. This includes both cerebral infarction or intracerebral and subarachnoid 
hemorrhage. A time window of 24 h distinguishes stroke from transient 
ischaemic attack (TIA), which is defined as a neurological deficit lasting less 
than 24 h. The term cerebrovascular disease compasses all vascular disease 
affecting the brain including stroke, vascular dementia, and asymptomatic 
cerebrovascular disease.
16
 
HISTORY: 
 Hippocrates (460-370 BC), first described stroke like symptoms as ‘the 
signs of impending apoplexy are attacks of numbness and anaesthesia’. Galen  
(131-201 A ) first described the anatomy of brain and its blood supply by 
animal dissection. Johan Jacob Wepfer (1629-1695) first described that 
occlusion of carotid and vertebral arteries are the cause of apoplexy and also 
bleeding inside brain as an important cause of stroke. Thomas Willis described 
the circular anastamosis of blood vessels at the base of brain and recognised 
transient ischemic attacks and embolic phenomenon.
16,17
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EPIDEMIOLOGY: 
Stroke is the third commonest cause of death worldwide, after coronary 
heart disease (CHD) and all types of cancer. Unlike the Caucasians, Asians have 
a higher prevalence of stroke. The number of persons who died from stroke was 
more than three times that for CHD, among the Asians.
17
 In one of the reports, 
the stroke mortality rate was 44 to 102.6/100,000 for males in Asia, when 
compared to 19.3 for  white males in Australia. 
 In 1980s, the prevalence rate of stroke were around 500-700 per 100,000 
in western countries and 900 per 100,000 in Asia.
18
 The first community-based 
study on stroke in India was done in Vellore in South India during 1969-71, and 
then a study in Rohtak during 1971-74.
19
 It was estimated that stroke 
represented 1.2 % of the total deaths in the country including all ages. The 
stroke death proportion increased with age and in > 70 years of age stroke 
contributed to 2.4% of all deaths. The gender ratio of death due to stroke was 
1.
20
 
PATHOPHYSIOLOGICAL CLASSIFICATION OF STROKE: 
ISCHAEMIC STROKE 
Large artery 
Cardioembolic 
Lacunar (small vessel disease) 
Other determined aetiology 
Undetermined aetiology 
21 
 
Multiple possible aetiologies
21,22 
CEREBRAL HAEMORRHAGE 
Primary subarachnoid haemorrhage 
Primary intracerebral haemorrhage 
 
DEFINITIONS: 
Large artery stroke:  
Occlusion or stenosis (>50%) in the large extracranial or intracranial 
cerebral arteries (carotid, vertebral, basilar, anterior cerebral, middle cerebral, 
posterior cerebral) with ischaemia in that arterial territory. 
Cardioembolic stroke:  
One or more of the following conditions: 
  Mechanical prosthetic heart valve, atrial fibrillation, myocardial 
infarction within last 2 months, dilated cardiomyopathy/congestive heart failure 
at stroke onset, endocarditis, sick sinus syndrome, atrial myxoma, left 
ventricular thrombus. 
Lacunar stroke: 
 Lacunar syndrome (pure motor stroke, pure sensory stroke, ataxic 
hemiparesis, clumsy hand dysarthria) characterised by either no lesion on brain 
imaging or a deep infarct (≤ 1.5 cm diameter) in the location consistent with the 
clinical syndrome.
21,22
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STROKE RISK FACTORS: 
A number of well recognised conventional risk factors for stroke are 
known already. They include both modifiable and non- modifiable factors. 
 
 Age:  
It  is one of the strongest risk factor for both cerebral infarction and  
haemorrhage. The incidence of stroke doubles with each successive decade 
above the age of 55 years (Wolfe 2000).  
Gender: 
Regarding gender, being a male is a risk factor for stroke. Overall, 
women will suffer stroke during their lifetime due to their greater life 
expectancy.  
Hypertension: 
Increase in blood pressure is a major risk factor for stroke. It has a strong 
and independent association with both ischemic and haemorrhagic stroke 
(Collins and Mac Mahon 1994). The stroke risk almost doubles with each 7.5 
mmHg increase in diastolic blood pressure.
23
  
 
Smoking: 
Studies showed that cigarette smoking is an important  risk factor of 
stroke. The relative risk is approximately 2. 
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Diabetes mellitus: 
The relative risk of stroke in association with diabetes is approximately 2–2.5. It 
is also a risk factor for atherosclerosis in casrotid arteries.  
Cholesterol: 
An Increase in total cholesterol and low-density lipoprotein cholesterol 
are strong risk factors for ischaemic heart disease while increased level of high-
density lipoprotein cholesterol seems to be protective. This relationship appears 
to be weak in case of stroke. Recent trials showed that, cholesterol reduction 
with statin therapy, reduces risk of stroke (Byington et al. 2001, Heart 
Protection Study Collaborative Group 2002). Also statins do have additional 
therapeutic effects such as reduce stroke incidence through atherosclerotic 
plaque stabilization and upregulation of endothelial nitric oxide synthase. 
 
Body mass index: 
It is an independent risk factor for stroke in both smokers and non-
smokers. A secondary increase in inflammation due to increased levels of 
cytokines in adipose tissue could be a mechanism through which obesity 
increases stroke risk. 
 
Physical exercise: 
Decreased physical activity is associated with an increased risk of stroke. 
Increase in physical exercise acts through reducing blood pressure.
23
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Plasma fibrinogen: 
The association between increased plasma fibrinogen and stroke is strong 
and consistent. This relationship is partly confounded by smoking as it increases 
stroke risk through increased fibrinogen.
24
 
Alcohol: 
Alcohol consumption in large volumes is a risk factor for stroke. This 
may due to increase in blood pressure and also due to atrial fibrillation or 
myocardial damage secondary to cardiomyopathy.  
Ethnicity: 
Among different ethnic groups, there is marked difference in incidence of 
stroke and the distribution of subtypes of the stroke. The incidence of stroke is 
increased in Black Americans and United Kingdom African Caribbeans 
compared with Caucasians (Gillum et al. 1999). Stroke incidence also appears 
to be higher in Chinese (Thorvaldsen et al. 1995), and intracranial 
atherosclerosis appears to be more common.
25
 
 
Homocysteine: 
Homocysteinuria is associated with very high levels of serum 
homocysteine is associated with an increased risk of stroke at an early age. This 
is due to endothelial dysfunction and accelerated atherogenesis or increased 
thrombosis.
26
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Socio-economic conditions: 
This is likely to act through a number of factor such as smoking, poor diet 
and lack of exercise which are all associated with low socio-economic status. 
Recent infection and inflammation: 
Majority of case control studies on ischaemic stroke showed an 
association between recent infection and stroke, which are determined by 
history of recent respiratory tract or other symptoms and by serological testing 
(Grau et al.1995). It occurs as a result of inflammatory changes which lead to a 
prothrombotic state and acute endothelial dysfunction.
27
  
 
Diet: 
Increased salt intake is associated with increased blood pressure. It is 
estimated that a 100 mmol increase in sodium intake will increase blood 
pressure by 10 mmHg which leads to about a 34 per cent increased risk of 
stroke (Law 1996). Higher vitamin C levels (high fruit and vegetable intake) are 
associated with a lower stroke risk which acts through an anti-oxidant effect. 
Folate may also reduce the stroke risk by reducing homocysteine concentration 
(Homocysteine Lowering Trialists’ Collaboration 1998). 
 
 Oral contraceptives: 
Studies showed a increased stroke risk associated with the oral 
contraceptive pill which is definite.
28
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Migraine: 
Stroke may complicate a migraine attack. Migraine itself appears to be a 
risk factor for stroke in young women. Studies have showed a positive 
association between migraine and stroke.
29
 
CardioVascular disease: 
Atrial fibrillation of both Rheumatic and non- Rheumatic origin are 
important risk factors for stroke.
30
  
Transient ischemic attacks: 
It is also an one of the risk factors for stroke. One out of every six 
patients would be affected by thrombotic stroke after two to four years. 
Polycythemia:  
It causes stroke due to hyperviscosity and sluggish blood flow. 
Prior stroke: 
The annual incidence of recurrent stroke is 142 per one lakh for the first 
stroke and 52 for subsequent stroke as observed by the national stroke survey.
30
 
 
PATHOPHYSIOLOGY OF ISCHEMIC STROKE: 
 Ischemic stroke can manifest as thrombotic stroke, embolic stroke, 
systemic hypoperfusion or venous thrombosis. Compromised blood perfusion is 
the basic pathology in (85–90%) of  strokes. The brain tissue is vulnerable 
ischemia because of low respiratory reserve and dependence on aerobic 
27 
 
metabolism. Therefore, core region undergoes immediate death, while 
penumbra region may be partially injured which has a potential to recover. 
 
CELLULAR LEVEL EFFECTS: 
Ischemia induced brain damage is by activation of the ischemic Cascade. 
This lead to local depletion of oxygen or glucose which leads to failure of 
production of ATP. This affect factors necessary for cell survival which are 
dependant on energy. This leads to a series of events resulting in cell injury and 
death. The extent of damage depends on duration, severity, and its location. 
The mechanisms involved in tissue injury/neuro protection are: 
• Depletion of cellular energy store due to failure of mitochondria. 
• Deleterious effects due to functional loss of membrane ion pumps.31 
• Release of excitatory neurotransmitters: 
Glutamate: 
 There is release of excitatory neurotransmitters due to ischemic cascade, 
like  glutamate and aspartate. The neuronal plasticity is maintained by glutamate 
which plays a vital role in it. But there will be an uncontrolled release of these 
transmitters in ischemic areas which mediate an excitotoxic synaptic 
transmission.The release of excitatory neurotransmitter, glutamate occur 
through six known mechanisms
32,33
:  
(i)  Reversal of uptake by transporters on plasma membrane,
34
 
(ii)  Cell swelling which results in anion channel opening ,  
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(iii)  Calcium dependent exocytosis, 
(iv)  The cystine–glutamate antiporter mediated glutamate exchange,35  
(v)  Ionotropic purinergic receptors mediated release.  
(vi) Unpaired connexons, ‘hemichannels’ which are functional, on the cell 
surface.
36
 
 
Synaptosomal-associated protein 25 (SNAP-25)
37
: 
 It is localised in nerve endings and axons. It is a neuron-specific protein 
and is involved in synaptic vesicle exocytosis,axonal outgrowth and  release of 
transmitter. 
Studies showed  that SNAP-25 is differentially regulated in ischemic 
stroke. Marti et al. demonstrated that there is increase in SNAP-25 mRNA 
levels in the infarct and penumbra region of stroke patients and it occurs mainly 
during the first 6 days after stroke. Astrocytes contain proteins that are essential 
for  glutamate sequestration into vesicles. Those proteins are
38 
: 
 
i) Vacuolar type H+-ATPase (V-ATPase) 
ii)  Vesicular glutamate transporters (VGLUT) 1, 2 and 3.
39   
 
• Production of  Reactive oxygen species and Oxygen free radicals40:  
These damage endothelium by reacting with them. It also initiates the 
apoptotic pathway. 
29 
 
• Apoptosis:  
It is known that necrosis occurs in ischemic core, likewise apoptosis 
occurs in the peripheral neurons.This results in an early gene expression of p53 
and Bcl-2
42
 and  release of pro-apoptotic molecules.
41
 
• Neuroprotection49: 
The ischemic cascade activates a variety of  neuroprotective mechanisms 
which  protect against cell death due to apoptosis and necrosis. These include: 
◦ Heat shock protein 70 (HSP70).43 
◦ Bcl-2 gene family.44 
◦ Prion protein (PrPc).45 
◦ Neurotrophin-3 (NT-3).46 
◦ Interleukin-10.47 
◦ Granulocyte-colony stimulating factor (G-CSF).48 
 
ISCHEMIC PENUMBRA: 
The ischemic cerebrovascular tissue has 2 layers: 
(a) Inner zone with severe ischemia having blood supply < 10–25%, 
which shows  necrosis of neurons and glial elements.  
(b) Outer zone with less severe ischemia (penumbra) that is supplied by 
collaterals. This zone contain cells that can be saved by timely therapeutic 
intervention.
50
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Immediately following an ischemic event, the centre core is perfused at 
10–12 ml/100 g/min or less and the ischemic area around it is hypoperfused at 
less than 18–20 ml/100 g/min. It is at risk of dying within hours. The penumbra 
is perfused at 60 ml/100 g/min and is less likely to die. Neurons in the 
penumbra are dysfunctional and may recover if reperfused in time. That is why  
the current protocols favour early pharmacologic intervention for re-
canalization.
51
 
 
CEREBRAL EDEMA: 
It accounts for much of the death and disability and hence of much 
concern. This attributes to the effect of neurogenic inflammation mediated 
through neuropeptides like substance P.  
Klatzo classified edema as: 
• Cytotoxic edema:  
This type of edema evolves within hours and is reversible. There will be 
swelling of the cellular elements of the brain like neurons, glia, and endothelial 
cells due to failure of ATP dependent ion transport and due to release of 
oxygen-derived free radicals. 
• Vasogenic edema:  
This type of edema occurs over hours and days. It  is irreversible. It 
causes increased permeability to serum proteins. This results in increased 
extracellular fluid volume and increased intracranial pressure (ICP). This causes 
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compartment shift within the brain and hence compresses neural structures and 
cerebral arteries. A sustained rise in intracranial pressure results in persistent 
ischemia and irreversible damage to brain cells.When severe may lead to 
cerebral herniation and potentially death.
52,53
 
EFFECTS ON STRUCTURAL INTEGRITY OF BRAIN: 
Hypoxia causes loss of structural integrity of brain and blood vessels 
mediated the release of matrix metalloproteases(MMP).
58
 The results in 
breakdown of the blood–brain barrier, which manifests as cerebral edema.54,55 
•  Angiogenesis56:  
This occurs through:  
(a) Inhibition of hypoxia-inducible factor-1 (HIF-1) degradation which 
inturn stimulates VEGF that is important for angiogenesis.  
(b)  Inflammation-associated infiltrates mediated by secretion of 
angiogenic growth factor. 
  • Activation of the immune mechanism by ischemia.57  
 ATHEROSCLEROSIS AND STROKE: 
The onset of atherosclerotic changes to precipitation of acute ischemic 
stroke is complex.  
The changes include
59
:  
(a) Fatty streak. 
 (b) Massive extracellular lipid at the branching points of vessels. 
 (c) Complicated fibrous plaques. 
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EVENTS IN ATHEROGENESIS: 
 (A) Injury to arterial wall
59
:  
 Ross had hypothesized that, atherosclerosis occurs due to effect of 
complex interplay among monocytes, lipoproteins, platelets, 
lymphocytes, and smooth muscle cells in the vascular intimal layer.  
(B)  Foam cell transformation by monocytes and  T- Lymphocytes.
60
 
 (C)  Oxidation of LDL-cholesterol. 
 (D)  Smooth muscle cell migration and its proliferation.
61
 
 (E) Platelet aggregation and adhesion along with denudation of epithelium.
62
 
 (F)  Fissuring of plaque and formation of thrombus.
63,64
 
• Subtypes of ischemic stroke due to thrombosis:  
◦ Atherothrombotic occlusion:  
This is the most common cause of primary large vessel occlusive 
cerebrovascular disease and also stroke. 
◦ Embolism: 
 They may due to cerebral arterial atherothrombosis and also may arise 
from other cardiac sources and deep vein thrombosis. 
◦ Microatheroma: 
They  are due to influx of fat like materials resulting in lipohyalinosis. It 
usually affect small vessels and causes lacunar strokes.
65
 
(G)  Plaque fissuring and its outcomes like partial or complete occlusion due to 
thrombus. 
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 (H) Cerebral atherothrombosis and its evolution:  
Thrombosis usually evolves over few minutes, or even take hours or 
days. 
A stroke that  progresses due to increasing occlusion and ischemia is 
called as ‘progressing stroke’ or ‘stroke in evolution’.  
(I) Hemorrhagic conversion: 
Ischemic stroke  have a ‘bland’ infarction associated with secondary 
bleeding. This is called as  hemorrhagic transformation (HT) or  hemorrhagic 
conversion. There will be a hematoma in parenchyma with a intraventricular 
extension which results in herniation due to midline shift. There will be 
macrophage invasion and leukocyte infiltration.
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STROKE AND INFLAMMATION: 
Inflammatory mechanism plays certain role in initiation and progression 
of stroke.  
 Inflammatory conditions: 
Stroke is seen in primary angitis of CNS, SLE, Systemic sclerosis, 
Sarcoidosis, Inflammatory bowel disease, Giant cell arteritis, Rheumatoid 
arthritis.
67
 
 Infective conditions: 
A variety of  infective conditions appeared to precede stroke. Mostly are 
respiratory pathogens and are bacterial origin like Chlamydia pneumonia
68
, 
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cytomegalovirus
69
 and Helicobacter pylori
70
, occurring within the previous 
month.  
Inflammatory mediators: 
The onset of ischemic cascade induces the initiation of inflammation, 
excitotoxicity, nitric oxide production, free radical damage and apoptosis, which 
all play a role in tissue injury. The molecular consequences due to brain 
ischemia include changes in cell signalling and its transduction, metabolism, 
gene regulation or expression.
76
 There will be release cytokines, like 
interleukin-1(IL-1) and tumor necrosis factor-α(TNF-α) after onset of ischemia 
which leads to  leucocyte activation, recruitment and adhesion to the 
endothelium.
71
 These leucocytes obstruct the vessel together with monocytes 
/macrophages. Reperfusion, and systemic inflammatory process also stimulate 
the inflammatory response, which hampers the effect of thrombolytic therapy.
72
 
Acute phase reactants: 
In the normal conditions, the body responds to inflammatory and 
infective conditions, by means of cytokines, primarily IL-6 and IL-1. The most 
important acute phase reactants in cerebrovascular ischemia are C-reactive 
proteins (CRP), serum amyloid A protein, and fibrinogen. 
C-reactive protein 
The median CRP concentration of healthy persons is roughly 1 mg/L. 
Increased CRP levels predict the risk of:  
(a) First episode of ischemic stroke; 
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 (b) Future TIA and ischemic stroke and fatal stroke in the elderly. 
There was a early increase in CRP within three hours of acute stroke and 
are therefore an independent predictor of nonfatal vascular event and survival 
after an ischemic stroke.
73
 
 Erythrocyte sedimentation rate (ESR): 
 Elevated ESR is an independent predictive factor of poor outcome within 
first month and early stroke recurrence.
74
 
Fibrinogen: 
There is hyperfibrinoginemia in patients with acute cerebral infarction 
together with leukocytosis and increased leukocyte aggregation.
75
 
Body temperature: 
Studies revealed that hypothermia of brain and body tends to reduce 
infarct size. Also that hyperthermia promotes neuronal damage. Body 
temperature has been related to initial stroke severity, lesion size, mortality, and 
outcome in stroke survivors. Raised body temperature in acute stroke, possibly 
due to infections has been associated with increased morbidity and 
mortality.
76,77
 
 Therapeutic intervention beyond thrombolytics: 
The recent protocols for primary stroke management and secondary 
prevention focuses mainly on modifiable risk factors like hypertension, 
smoking, carotid stenosis, atrial fibrillation, physical inactivity, diabetes 
mellitus, and dyslipidemia, with usage of drugs like antiplatelet agents, 
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antihypertensive drugs, lipid-lowering agents, and anticoagulant drugs. A recent 
addition was intravenous tissue plasminogen activator in cases of acute 
ischemic stroke. Its efficacy is often limited by severity of the stroke, older age 
group, hypertension especially systolic, site of occlusion, collateral blood 
supply, and time from onset to treatment, and reperfusion-associated 
inflammation. The overall recanalization rate in thrombolytic therapy varies 
from 46.2% during the first 6–24 h of intravenous administration, to 63.2% in 
intraarterial and 83.6% with mechanical reperfusion techniques.
78
 
 
Currently available agents with anti-inflammatory role: 
Aspirin: 
  Aspirin has a direct role in modifying CRP levels, thus raising the 
possibility of an anti-inflammatory action apart from its antiplatelet effect 
mediated via COX inhibition.
79,80
 
Statins
81
: 
Statins reduces the incidence of ischemic stroke in patients with coronary 
artery disease significantly, both with and without elevated serum cholesterol 
concentrations. Statins have the ability to reduce CRP levels. Statins also causes 
plaque stabilization and even regression in some cases. It has a neuroprotective 
action by upregulation of endothelial NOS and inhibition of  iNOS, an effect 
associated with augmented cerebral blood flow and reduced infarct size. 
Recently, Stroke Prevention by Aggressive Reduction in Cholesterol Levels 
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study showed that treatment with high dose atorvastatin reduced risk of stroke 
in patients with recent stroke and transient ischemic attack and no known 
coronary artery disease (CAD).
82,83
 
 
Angiotensin converting enzyme inhibitors and angiotensin II receptor 
blockers: 
Angiotensin II has proinflammatory effects via augmentation of 
expression of VCAM-1, MCP-1, and IL-6, and increased production of reactive 
oxygen species, which can be countered by angiotensin converting enzyme 
inhibitors or angiotensin II receptor blockers for having anti-inflammatory 
effect.
83
 
 
Novel therapeutic agents with anti-inflammatory role: 
Neuroprotective agents:  
This includes a wide variety of drugs that act by restricting damage and 
thereby salvages the penumbral tissue. They act by excitatory neurotransmitter 
modulation, influx of calcium and its control. They also may be activators of 
metabolic pathways, antiedema drugs, adhesion of leukocyte inhibitors and free 
radical scavengers. Unfortunately, despite the safety and efficacy being proved 
by more than 100 clinical trials its translation into clinical practice remains 
awaited
84
. Edaravone is the first clinical neuroprotective drug which has been 
used for ischemic stroke from 2001 in Japan.
85
 The diet rich in fruits and 
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vegetables have a lower cardiovascular risk, possibly due to antioxidant 
nutrients: vitamin C, vitamin E, beta-carotene. They inhibit LDL oxidation and 
also by decreases fibrinogen and there by reduces the formation of atheroma.
86
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AIM OF THE STUDY: 
 
•  To evaluate the prognostic significance of serum fibrinogen with stroke 
severity by correlation with clinical outcome stroke scales. 
 
• To evaluate the correlation between serum fibrinogen and  various factors 
in stroke patients like: 
• Age  
• sex 
• Hypertension 
• Diabetes mellitus 
• Smoking 
• Alcohol 
• Hypercholesterolemia 
• Body mass index 
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BACK GROUND: 
 
SELECTION OF SUBJECTS: 
  Patients admitted with history of acute onset of stroke in medical 
wards in the Department of Medicine, Kilpauk Medical College Hospital were 
enrolled in after excluding the exclusion criteria. 
  Age and sex matched persons not having focal neurologic deficit 
and after verifying exclusion criteria via questionnaire were taken as controls. 
 
INCLUSION CRITERIA: 
 
 All patients presenting with new onset focal neurological 
deficit following ischemic stroke, within 48 hours of onset of 
stroke are  taken into study.  
 
 Patients with new onset stroke with risk factors of 
hypertension, diabetes mellitus, dyslipidemia, smoking, 
alcohol were included. 
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EXCLUSION CRITERIA: 
• Elderly Patients (> 80 years) were excluded.  
• Individuals with associated Connective Tissue disorders and  
Rheumatic heart disease, Coronary Artery disease were 
excluded.  
• Patients with chronic kidney disease, uremia were excluded. 
• Patients with infective, malignant etiology for stroke were 
excluded. 
• Patients with liver diseases like cirrhosis were excluded. 
• Patients with history of Transient ischemic attacks (TIA) or 
Reversible ischemic neurological deficit (RIND), 
cerebrovascular accidents (CVA) were excluded.  
• Haemorrhagic Stroke Patients (ICH, SDH) were excluded 
with the aid  of CT scan. 
• History of recent surgery and trauma. 
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MATERIALS AND METHODS: 
Setting :  Kilpauk Medical College. 
Study design:  prospective Cross sectional study 
Period of study:  6 months from March 2013 to August 2013. 
Sample size:  100 subjects ( 50 cases + 50 controls ) 
Both cases and controls are investigated by following measures. 
1) A detailed medical history including present, past, family and personal 
history were asked. 
2) General examination. 
3) Vitals monitoring including blood pressure, pulse rate . 
4) Body mass index. 
5) Detailed neurologic examination. 
6) Examination of other systems. 
7) Severity score using National Institute of Health Sciences Scale at 
admission. 
8) Complete blood count. 
9) Renal function test. 
10) Serum cholesterol. 
11) Serum fibrinogen. 
12) ECHO cardiogram. 
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13) CT brain plain. 
14) Reassessment of morbidity and mortality using Modified Rankin’s 
scale scores at one month follow-up. 
 
Biochemical analysis: 
  After overnight fasting, blood samples were taken in the morning. 
Blood sugar, cholesterol and fibrinogen were measured.  
 The plasma fibrinogen level was measured quantitatively by Clauss 
method. 
Principle: 
   Fibrinogen is a soluble plasma protein which is converted to an insoluble 
polymer mediated through thrombin, resulting in clot formation. This 
thrombin mediated clotting time of diluted plasma is inversely proportional 
to fibrinogen concentration of the plasma. 
Test : 
 Venous blood is collected in an evacuated siliconized tube containing 1 
volume 0.11 mol/lt of sodium citrate (3.8%) and 9 volumes of whole blood 
which is centrifuged for 15 minutes at RCF of 2000 g. the buffer provided in 
the kit is used to prepare 1: 10 dilution of patient’s plasma sample. 
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Assay : 
 0.2 ml of diluted (50μl) citrated plasma is incubated for one minute then 
25 μl of thrombin reagent is added at room temperature and clotting time is 
then determined at 37˚ C using a coagulation instrument. The fibrinogen 
concentration is then determined by matching the clotting time from the 
standard provided and prepared in the kit. 
 
DATA ANALYSIS: 
Statistical analysis: 
 Mean values of all parameters in subgroups were calculated by 
independent sample-t- test. To compare the distributions of dichotomous 
data viz., gender, age, smokers, presence of hypertension or diabetes and 
fibrinogen levels, Chi-square test was used. Association between acute 
ischemic stroke and fibrinogen level was assessed by logistic regression 
model. ANOVA test was used to assess the association between stroke scales 
and fibrinogen level. 
 All statistical analyses were performed using SPSS (software package 
used for statistical analysis) package. A p-value of less than 0.05 was 
considered to be statistically significant. 
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OBSERVATION ANALYSIS: 
TABLE: 1. AGE WISE DISTRIBUTION AMONG CASES AND CONTROLS 
  
 
  
 
 
 
The minimum age of the patients in cases and controls was 35 years and the 
maximum age was 75 years. Among 50 cases, 6% were in 30-39 years, 22% 
were in 40-49 years, 22% were in 50-59 years, 28% were in 60-69 years and 
22% were in 70-79 years. Likewise, among 50 controls, there were 6%, 22%, 
22%, 28%, 22% in each of the above groups respectively. 
CHART: 1. AGE WISE DISTRIBUTION AMONG CASES AND 
CONTROLS: 
 
0 
2 
4 
6 
8 
10 
12 
14 
30-39 
40-49 
50-59 
60-69 
70-79 
CASES 
CONTROLS 
AGE CASES CONTROLS 
30-39 3 3 
40-49 11 11 
50-59 11 11 
60-69 14 14 
70-79 11 11 
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TABLE: 2. SEX DISTRIBUTION AMONG CASES AND CONTROLS 
   
  
 
 
The total number of cases and controls were 50 respectively. Among the 
cases, 31 were male and 19 were females. i.e., 62% were male among cases and 
38% were female among cases. Likewise, among 50 controls, 62% (31) were 
males and 38% (19) were females. 
CHART: 2. SEX DISTRIBUTION AMONG CASES AND CONTROLS. 
 
 
0 
5 
10 
15 
20 
25 
30 
35 
CASES CONTROLS 
MALE 
FEMALE 
SEX CASES CONTROLS 
MALE 31 31 
FEMALE 19 19 
TOTAL 50 50 
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TABLE: 3. MEAN FIBRINOGEN LEVEL AMONG CASES AND 
CONTROLS. 
 
NUMBER 
MEAN 
FIBRINOGEN 
STANDARD 
DEVIATION 
STD. 
ERROR OF 
MEAN P-VALUE 
CASES 50 612.2 186.069 26.314 
 
0.001 CONTROLS 50 296.8 134.854 19.071 
 
 The mean fibrinogen level among 50 cases was 612.20 mg% and the 
mean fibrinogen level among controls was 296.80 mg%. The p-value for mean 
fibrinogen between cases and controls was 0.001.  
There was statistically significant difference between mean fibrinogen 
level between cases and controls. 
CHART: 3. MEAN FIBRINOGEN LEVEL AMONG CASES AND 
CONTROLS 
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TABLE: 4. MEAN FIBRINOGEN LEVEL AMONG AGE GROUPS IN 
CASES AND CONTROLS 
 
The mean fibrinogen level increases as age group increases both in cases 
and controls. The p- value for age group 30-39 was 0.109 and for other groups it 
was 0.001. Therefore, there was statistically significant difference between 
mean fibrinogen level between cases and controls in all age groups except 30-39 
years age-group, in which it was not significant. 
 
 
 
 
AGE IN 
YEARS 
MEAN FIBRINOGEN 
P-VALUE 
CASES CONTROLS 
MEAN  S.D S.E. MEAN S.D. S.E. 
30-39 520 262.3 151.438 206.67 28.87 16.667 0.109 
40-49 573.64 223.93 67.518 270 92.09 27.765 0.001 
50-59 599.09 186.2 56.14 308.18 124.73 37.606 0.001 
60-69 631.43 179.61 48.002 312.86 166.52 44.505 0.001 
70-79 664.55 145.7 43.929 316.36 157.18 47.391 0.001 
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CHART: 4. MEAN FIBRINOGEN LEVEL AMONG AGE GROUPS IN 
CASES AND CONTROLS 
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TABLE: 5. SEX WISE MEAN FIBRINOGEN LEVEL AMONG CASES AND 
CONTROLS. 
SEX 
GROUP 
MEAN FIBRINOGEN 
P-VALUE 
CASES CONTROLS 
MEAN S.D. S.E. MEAN S.D. S.E. 
MALE 590.32 197.37 35.449 350.65 139.76 25.102 0.001 
FEMALE 647.89 164.78 37.802 208.95 61.72 14.161 0.001 
 
The mean fibrinogen level for males in cases was 590.32 and in controls 
it was 350.65 with a p value of 0.001.The mean fibrinogen value for females in 
cases was 647.89 and in controls it was 208.95 with a p-value of 0.001. 
Therefore, there was a statistically significant difference between mean 
fibrinogen level in both sexes between cases and control. But among cases, the 
mean fibrinogen level was greater in females than males. 
CHART: 5. SEXWISE MEAN FIBRINOGEN LEVEL AMONG CASES AND 
CONTROLS. 
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TABLE:6. NUMBER OF HYPERTENSIVES AND NORMOTENSIVES 
AMONG CASES AND CONTROLS. 
 
 
 
 
The number of hypertensives in cases was 22 which constitutes 44% of 
total cases and normotensives was 28, which constitutes 56% of total 50 cases. 
Likewise in controls, hypertensives were 44% and normotensives were 56%. 
 
CHART: 6. NUMBER OF HYPERTENSIVES AND NORMOTENSIVES 
AMONG CASES AND CONTROLS. 
 
 
0 
5 
10 
15 
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25 
30 
cases controls 
hypertensive 
normotensive 
 CASES CONTROLS 
HYPERTENSIVE 22 22 
NORMOTENSIVE 28 28 
TOTAL 50 50 
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TABLE: 7. MEAN FIBRINOGEN LEVEL AMONG HYPERTENSIVES AND 
NORMOTENSIVES IN CASES AND CONTROLS 
 
MEAN FIBRINOGEN 
P-VALUE 
CASES CONTROLS 
MEAN S.D. S.E. MEAN S.D. S.E. 
HYPERTENSIVE 561.36 198.67 42.356 315.45 157.23 33.522 0.001 
NORMOTENSIVE 652.14 168.44 31.833 282.14 115.19 21.769 0.001 
  
The mean fibrinogen level among hypertensives among cases was 561.36 
and in controls it was 315.45 with a p- value of 0.001. The mean fibrinogen 
level among normotensives in cases was 652.14 and in controls it was 282.14 
with a p value of 0.001. There was a statistically significant difference between 
mean fibrinogen level between hypertensive cases and controls, and also 
between normotensive cases and controls.  
In cases, the mean fibrinogen level was more in normotensives than 
hypertensives. 
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CHART: 7. MEAN FIBRINOGEN LEVEL AMONG HYPERTENSIVES 
AND NORMOTENSIVES IN CASES AND CONTROLS. 
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TABLE: 8. NUMBER OF PERSONS WITH DIABETES AMONG CASES 
AND CONTROLS. 
 
 
 
 
 
  
Among 50 cases, 30% i.e., 15 were having diabetes and 70% (35) not having  
diabetes. Likewise, among 50 controls, 30% were diabetics and 70% were non- 
diabetics. 
CHART: 8. NUMBER OF DIABETICS AMONG CASES AND CONTROLS. 
 
 
0 5 10 15 20 25 30 35 40 
cases 
controls 
non-diabetes 
diabetes 
 CASES CASES 
DIABETES 15 15 
NON-
DIABETES 
35 35 
TOTAL 50 50 
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TABLE:9. MEAN FIBRINOGEN LEVEL AMONG DIABETICS AND NON- 
DIABETICS IN CASES AND CONTROLS. 
 
 
MEAN FIBRINOGEN 
P-VALUE 
CASES CONTROL 
MEAN S.D. S.E. MEAN S.D. S.E. 
DIABETES 542.67 209.91 54.2 272.67 133.5 34.468 0.001 
NON-
DIABETES 642 169.42 28.638 307.14 136.03 22.993 0.001 
 
 
The mean fibrinogen level among diabetics in cases was 542.67 which is 
higher than the mean fibrinogen for diabetics in control,which was 272.67 with 
a p- value of 0.001 and it was statistically significant. 
 Similarly, the mean fibrinogen level among non-diabetics in cases was 
642 and in controls was 307.14 with a p- value of 0.001, which was statistically 
significant. Among cases and controls, the mean fibrinogen level was higher in 
non-diabetics than diabetics. 
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CHART: 9. MEAN FIBRINOGEN LEVEL AMONG DIABETICS AND 
NON-DIABETICS IN CASES AND CONTROLS. 
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TABLE:10. NUMBER OF SMOKERS AND NON-SMOKERS AMONG 
CASES AND CONTROLS 
  
 
 
 
 
 
 Among the 50 cases, 46% (23) were smokers and 54% (27) were non- 
smokers. Among the 50 controls, 46% were smokers and 54% were non- 
smokers.  
CHART:10. NUMBER OF SMOKERS AND NON-SMOKERS AMONG 
CASES AND CONTROLS. 
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TABLE: 11. MEAN FIBRINOGEN LEVEL AMONG SMOKERS AND NON-
SMOKERS IN CASES AND CONTROLS. 
 
 
MEAN FIBRINOGEN 
P-VALUE 
CASES CONTROLS 
MEAN S.D. S.E. MEAN S.D. S.E. 
SMOKER 594.78 202.84 42.295 332.17 148.05 30.87 0.001 
NON-
SMOKER 627.04 173.02 33.298 266.67 116.95 22.507 0.001 
 
The mean fibrinogen level among smokers in cases was 594.78 and the 
mean fibrinogen level among smokers in controls was 332.17 with a p-value of 
0.001.  
Similarly, the mean fibrinogen level among non-smokers in cases was 627.04 
and non-smokers in controls was 266.67 with a p-value of 0.001. 
 Therefore, there was a statistically significant difference between mean 
fibrinogen levels both among smokers and non-smokers between cases and 
controls.   
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CHART: 11. MEAN FIBRINOGEN LEVEL AMONG SMOKERS AND 
NON-SMOKERS IN CASES AND CONTROLS. 
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TABLE: 12. NUMBER OF ALCOHOLICS AND NON-ALCOHOLICS  
AMONG CASES AND CONTROLS. 
 CASES CONTROLS 
ALCOHOLICS 14 14 
NONALCOHOLICS 36 36 
TOTAL 50 50 
   
Among the 50 cases, 28% (14) were alcoholics and 72% (36) were non-
alcoholics. Likewise, among 50 controls, 28% (14) were alcoholics and 72% 
(36) were non-alcoholics. 
CHART: 12. NUMBER OF ALCOHOLICS AND NON-ALCOHOLICS  
AMONG CASES AND CONTROLS. 
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TABLE: 13. MEAN FIBRINOGEN LEVEL AMONG ALCOHOLICS AND 
NON-ALCOHOLICS IN CASES AND CONTROLS. 
 
 
MEAN FIBRINOGEN 
P-VALUE 
CASES CONTROLS 
MEAN S.D. S.E. MEAN S.D. S.E. 
ALCOHOL 577.14 188.08 50.268 328.57 133.06 35.562 0.001 
NON-
ALCOHOL 625.83 186.14 31.023 284.44 135.36 22.56 0.001 
  
The mean fibrinogen level among alcoholics in cases was 577.14 and the 
mean fibrinogen level among alcoholics in controls was 328.57 with a p-value 
of 0.001. 
 Similarly, the mean fibrinogen level among non-alcoholics in cases was 
625.83 and the mean fibrinogen level among non-alcoholics in controls was 
284.44 with a p-value of 0.001. 
 Therefore, there was a statistically significant difference between mean 
fibrinogen level both among alcoholics and non-alcoholics between cases and 
controls. 
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CHART: 13. MEAN FIBRINOGEN LEVEL AMONG ALCOHOLICS AND 
NON- ALCOHOLICS IN CASES AND CONTROLS. 
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TABLE:14. NUMBER OF OBESE AND NON-OBESE PERSONS AMONG 
CASES AND CONTROLS. 
 
 
 
 
 
 Among, the 50 cases, 25 (50%) were obese and 25 (50%) were non- 
obese. Likewise in 50 controls, 50% were obese and 50% were non- obese. 
 
CHART: 14. NUMBER OF OBESE AND NON-OBESE AMONG CASES 
AND CONTROLS. 
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TABLE: 15. MEAN FIBRINOGEN LEVEL AMONG OBESE AND NON-
OBESE IN CASES AND CONTROLS. 
 
 
MEAN FIBRINOGEN 
P-VALUE 
CASES CONTROLS 
MEAN S.D. 
STD. 
ERROR MEAN S.D. 
STD. 
ERROR 
OBESE 733.6 57.146 11.429 312 131.846 26.369 0.001 
N0N-
OBESE 490.8 191.614 38.323 281.6 138.795 27.759 0.001 
  
The mean fibrinogen level among obese in cases was 733.60 and the 
mean fibrinogen level among obese in controls was 312 with a p-value of 0.001.  
Similarly, the mean fibrinogen level among non-obese in cases was 490.8 
and mean fibrinogen level among non-obese in controls was 281.60 with a p-
value of 0.001. 
Therefore, there was a statistically significant difference between mean 
fibrinogen level both among obese and non- obese between cases and controls. 
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CHART: 15. MEAN FIBRINOGEN LEVEL AMONG OBESE AND NON-
OBESE IN CASES AND CONTROLS. 
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TABLE:16. NUMBER OF PERSONS WITH HYPERCHOLESTEROL AND 
NORMAL CHOLESTEROL AMONG CASES AND CONTROLS. 
 
 
 
 
 
 
 Among 50 cases, 60% (30) had hypercholesterol and 40% (20) had 
normal cholesterol levels. Likewise, 30 (60%) in controls had hypercholesterol 
and 20 (40%) had normal cholesterol. 
 
CHART: 16. NUMBER OF PERSONS WITH HYPERCHOLESTEROL 
AMONG CASES AND CONTROLS. 
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TABLE:17. MEAN FIBRINOGEN LEVEL AMONG PERSONS WITH 
HYPERCHOLESTEROL AND NORMAL CHOLESTEROL IN CASES AND 
CONTROLS. 
 
 
MEAN FIBRINOGEN 
P-
VALUE 
CASES CONTROLS 
MEAN S.D. 
STD. 
ERROR MEAN S.D. 
STD. 
ERROR 
HYPERCHOLESTEROL 662 164.283 43.763 304.67 128.378 23.439 0.001 
NORMAL 
CHOLESTEROL 537.5 195.714 43.763 285 146.629 32.787 0.001 
 
 The mean fibrinogen level among patients with hypercholesterol in cases 
was 662 and in controls was 304.67 with a p-value of 0.001. 
 Similarly, the mean fibrinogen level among patients with normal 
cholesterol in cases was 537.5 and in controls was 285 with a p-value of 0.001. 
 Therefore, there was a statistically significant difference between mean 
fibrinogen level both among persons with hypercholesterol and normal 
cholesterol between cases and controls. 
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CHART: 17. MEAN FIBRINOGEN LEVEL AMONG PERSONS WITH 
HYPERCHOLESTEROL AND NORMAL CHOLESTEROL IN CASES AND 
CONTROLS. 
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TABLE:18. NIHSS SCORE AMONG CASES AND THEIR MEAN 
FIBRINOGEN LEVEL. 
 
NIHSS SCORE NUMBER 
MEAN FIBRINOGEN 
MEAN S.D. 
STD. 
ERROR 
MILD(<5) 10 312 110.635 34.986 
MODERATE(6-15) 13 560 93.452 25.919 
SEVERE (16-25) 10 710 11.547 3.651 
VERY SEVERE( >25) 17 771.18 33.89 8.22 
 
 The severity of ischemic stroke was graded using National  Institute of 
Health Stroke Scale score during admission. Based on the scores, the cases were 
classified as mild (score < 5), moderately severe ( score 6 - 15), severe ( score 
16 – 25) and very severe ( score > 25).  
Among the cases, 10 had mild stroke, 13 had moderately severe stroke, 
10 had severe stroke and 17 had very severe stroke.  
The mean fibrinogen level among mild cases was 312. The mean 
fibrinogen among moderately severe cases was 560. The mean fibrinogen level 
among severe cases was 710 and the mean fibrinogen level among very severe 
cases was 771.18. 
Hence, it was obvious that the stroke severity increases with increased 
fibrinogen levels in cases during admission. 
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CHART: 18. NIHSS SCORE AMONG CASES AND THEIR MEAN 
FIBRINOGEN LEVEL. 
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TABLE: 19. MODIFIED RANKIN’S SCALE SCORE AT 1 MONTH 
AMONG CASES AND THEIR MEAN FIBRINOGEN LEVEL. 
MRS SCORE AT 
1 MONTH NUMBER 
MEAN FIBRINOGEN 
MEAN S.D. STD. ERROR 
0 7 258.57 83.95 31.73 
1 7 441.43 32.367 12.234 
2 4 557.5 5 2.5 
3 11 683.64 33.548 10.115 
4 9 734.44 22.423 7.474 
5 9 764.44 25.55 8.517 
6 3 823.33 37.859 21.858 
 
 The cases were followed up for one month and the morbidity and 
mortality were assessed using Modified Rankin’s Scale at one month after the 
stroke onset. Based on the morbidity, the cases were assigned scores from 0 to 
6(0 for no symptoms and 6 for death). 
  Among the 50 cases, 7 cases with mean fibrinogen level of 258.57 had 
no symptoms  (score 0), another 7 cases with mean fibrinogen level of 441.43 
had no significant disability despite symptoms (score1), 4 cases with mean 
fibrinogen level of 557.50 had slight  disability (score 2), 11 cases with mean 
fibrinogen level of 683.64 had moderately severe disability (score 3), 9 cases 
with mean fibrinogen level of 734.44 had severe disability (score 4), another 9 
with mean fibrinogen level of 764.44 had very severe disability (score 5) and 3 
cases with mean fibrinogen level of 823.33 were dead (score 6). Hence, the 
severity and prognosis of stroke were worse with increased fibrinogen levels 
during admission. 
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CHART: 19. MODIFIED RANKIN’S SCALE SCORE AT 1 MONTH 
AMONG CASES AND THEIR MEAN FIBRINOGEN LEVEL. 
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DISCUSSION: 
 
  A total of 100 patients were enrolled in our study which comprises of 50 
patients with acute ischemic stroke (study group) and 50  persons without stroke 
( control group). 
 The mean age of study group was 57.72 with a standard deviation of 
11.898 and standard error of mean of 1.683. the mean age of control group was 
57.64 with standard deviation of 11.955 and standard error of mean of 1.691. 
There was no statistical difference in the two groups (p > 0.05) regarding the 
baseline characteristics such as age, sex, diabetes, hypertension, smoking, 
alcohol, obesity and hypercholesterolemia. The two groups were statistically 
matched regarding baseline characteristics. 
 
FIBRINOGEN LEVEL BETWEEN CASES AND CONTROL GROUP: 
 The mean fibrinogen level among cases was 612.20 with a standard 
deviation of 186.069 and standard error of mean 26.314. 
 Likewise, the mean fibrinogen level among control group was 296.80 
with standard deviation of 134.854 and standard error of mean 19.071, with a p 
value of 0.001 (< 0.05) which was statistically significant. 
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SI.NO STUDY STUDY POPULATION 
MEAN FIBRINOGEN P- 
VALUE CASES CONTORLS 
1 HAZRA B ET AL 
63 PATIENTS, 30 
CONTOLS 378.67 216.67 <0.01 
2 MISTRY P ET AL 
56 PATIENTS, 40 
CONTROLS 534±74 445.78±92.28 <0.01 
3 
AMITH KUMAR ET 
AL 50 CASES , 50 CONTROLS 
602±197.246
3 
301±141.453
8 <0.05 
4 OUR  STUDY 50 CASES , 50 CONTROLS 612.2 296.8 0.001 
 
 Similar to the above studies, the current study also demonstrated a 
significant increase in serum fibrinogen levels in ischemic stroke patients when 
compared with controls. Hazra B et al, Amith kumar et al  studies include 
patients with both ischemic and hemorrhagic stroke in study group whereas 
current study includes only ischemic stroke patients. 
 The study group comprises of 50 patients with acute ischemic stroke.  
Among the study group, 44% (22) were hypertensive, 30% (15) were diabetics, 
46% ( 23) were smokers, 28% (14) were alcoholics, 50% (25) were obese, 60% 
(30) were having hypercholesterolemia.  
 The mean fibrinogen level in the study group increases as age advances, 
which was higher than that of control group, with a p- value of 0.001 which was 
statistically significant. 
 The mean fibrinogen level among males and females in study group was 
higher than control group which was statistically significant (p<0.05). 
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In the study group, the mean fibrinogen level of hypertensive, diabetic, 
smokers, alcoholic, obese and hypercholesterolic patients were higher than that 
of seen in control groups, which was statistically significant. 
Likewise, the mean fibrinogen level of normotensive, non diabetic, non 
smokers, non alcoholics, non obese and normal cholesterol patients in study 
group were higher than that of control group which was also statistically 
significant (p<0.05). 
The mean fibrinogen level is higher in patients with higher NIHSS score 
i.e., very severe neurologic impairment and lowest in patients with mild 
impairment, NIHSS score <5. 
The mean fibrinogen level in mild impairment cases was 312, moderately 
severe cases was 560, severe cases was 710 and very severe cases was 771.18. 
Hence, it was clear that the fibrinogen levels were higher in patients with acute 
ischemic stroke with very severe impairment. 
After one month of acute ischemic stroke onset, the morbidity and 
mortality were assessed using Modified Rankin’s Scale (MRS). It was found 
that the outcome was worse in cases with higher fibrinogen levels. There were 3 
dead with a MRS score of 6 and mean fibrinogen level of 823.33. 
The mean fibrinogen level in patients with no symptoms at one month 
after stroke onset was 258.57 (MRS score 0). The mean fibrinogen level in 
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patients with MRS score of 1 was 441.43 and they had no significant disability 
despite symptoms. The mean fibrinogen level in patients with slight disability 
(MRS score2) was 557.50. The mean fibrinogen level for MRS score of 3, 4 and 
5 were 683.64, 734.44 and 764.44 respectively. 
Hence, it was clear that among the cases, the acute ischemic stroke was 
very severe in patients with higher fibrinogen levels. Also, the outcome at the 
end of one month was poor in patients with higher fibrinogen levels during 
stroke onset. 
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CONCLUSION: 
1. Serum fibrinogen level was higher in patients with acute ischemic 
stroke compared to controls. 
2. Among the patients with acute ischemic stroke, the higher serum 
fibrinogen level correlates with: 
a. Clinical severity assessed by National Institute Of  Health 
Stroke Scale. 
b. Poor prognosis and stroke outcome at end of one month after 
stroke onset, assessed by Modified Rankin’s Scale. 
 
CLINICAL SIGNIFICANCE: 
 Fibrinogen is associated with risk factors for stroke. Therefore, elevated 
fibrinogen levels provide a mechanism for the risk factors to exert their effect. 
Fibrinogen is increased following an acute stroke as an acute phase reactant. 
Also, fibrinogen predicts vascular events in established atherosclerotic 
disorders. Hence, chronically raised fibrinogen in high risk individuals appears 
to be an independent risk factor for stroke. 
 Measures such as cessation of smoking, weight reduction, increased 
physical activity and control of blood pressure decreases plasma fibrinogen 
level, thereby reduces stroke occurrence in high risk individuals in future. 
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 Therefore, plasma fibrinogen measurement can be used as a screening for 
at risk persons for stroke and other vascular events and also as a prognostic 
marker following an acute stroke. The measures to decrease plasma fibrinogen 
levels can be included in preventive strategies against stroke.  
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 PROFORMA 
 
NAME:       
AGE:   
SEX: 
OCCUPATION:        
IP.No.: 
RISK FACTORS:       YES/NO 
 1. SYSTEMIC HYPERTENSION   
 2. DIABETES MELLITUS    
 3. SMOKING      
 4. ALCOHOL      
 5. IHD       
 6. RHD       
 7. AF        
 8. PREVIOUS HISTORY OF STROKE  
 9. HIGH CHOLESTEROL   
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SIGNS: 
 GENERAL 
 Built:    Pallor:   Icterus: 
 Pedal oedema:  Fever:             cyanosis: 
 Clubbing:   PR:                               BP: 
 BMI :           
SYSTEM EXAMINATION: 
CVS: 
 
RS : 
 
PER ABDOMEN: 
 
CNS: 
 SYMPTOMS: 
  1. HEAD ACHE    +/- 
  2. VOMITING    +/- 
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  3. LOSS OF CONSCIOUSNESS +/- 
  4. GIDDINESS    +- 
  5. CONVULSIONS   +/- 
  6. GAIT DISTURBANCES  +/- 
  7. SPEECH DISTURBANCES  +/- 
 
  
SIGNS: 
  1. DIPLOPIA    +/- 
  2. SPEECH DEFICIT   +/- 
  3. CRANIAL NERVE INVOLVMENT 
  4. MOTOR DEFICIT 
  5. SENSORY DEFICIT 
  6. CEREBELLAR SIGNS  
  7. NIHSS SCORE   MILD/MODERATE/SEVERE 
  8. MRS AFTER ONE MONTH  
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INVESTIGATIONS 
BLOOD: 
COMPLETE HAEMOGRAM - Hb. 
                                         TC   
                                          DC 
                                         ESR 
                               PLATELETS 
              BLOOD – Sugar 
                                        Urea 
                                Creatinine 
    Serum electrolytes Sodium 
                               Potassium 
               Serum Triglycerides 
                  Serum cholesterol 
            Serum fibrinogen 
URINE ROUTINE :           
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CHEST X RAY 
ECG 
ECHO 
CT BRAIN 
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NIHSS SCALE 
1a. Level of Consciousness: 
0 = Alert; keenly responsive. 
1 = Not alert, but arousable by minor stimulation to obey, answer, or respond. 
2 = Not alert, requires repeated stimulation to attend, or is obtunded and 
requires strong or painful stimulation to make movements (not stereotyped). 
3 = Responds only with reflex motor or autonomic effects or totally 
unresponsive, flaccid, areflexic. 
Score: 
1b. LOC Questions:  
0 = Answers both questions correctly. 
1 = Answers one question correctly. 
2 = Answers neither question correctly. 
Score: 
1c. LOC Commands:  
0 = Performs both tasks correctly 
1 = Performs one task correctly 
2 = Performs neither task correctly 
Score: 
2. Best Gaze:  
0 = Normal 
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1 = Partial gaze palsy. This score is given when gaze is abnormal in one or both 
eyes, but where forced deviation or total gaze paresis are not present. 
2 = Forced deviation, or total gaze paresis not overcome by the oculocephalic 
maneouver. 
Score: 
3. Visual:  
0 = No visual loss 
1 = Partial hemianopia 
2 = Complete hemianopia 
3 = Bilateral hemianopia (blind including cortical blindness) 
Score: 
4. Facial Palsy:  
0 = Normal symmetrical movement 
1 = Minor paralysis (flattened nasolabial fold, asymmetry on smiling) 
2 = Partial paralysis (total or near total paralysis of lower face) 
3 = Complete paralysis of one or both sides (absence of facial movement in the 
upper and lower face) 
Score: 
5 & 6. Motor Arm and Leg:  
0 = No drift, limb holds 90 (or 45) degrees for full 10 seconds. 
1 = Drift, Limb holds 90 (or 45) degrees, but drifts down before full 10 seconds; 
does not hit bed or other support. 
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2 = Some effort against gravity, limb cannot get to or maintain (if cued) 90 (or 
45) degrees, drifts down to bed, but has some effort against gravity. 
3 = No effort against gravity, limb falls. 
4 = No movement 
9 = Amputation, joint fusion , explain: --------- 
Score:    5a.Left Arm                    5b. Right Arm 
0 = No drift, leg holds 30 degrees position for full 5 seconds. 
1 = Drift, leg falls by the end of the 5-second period but does not hit bed. 
2 = Some effort against gravity; leg falls to bed by 5 seconds, but has some 
effort against gravity. 
3 = No effort against gravity, leg falls to bed immediately. 
4 = No movement 
9 = Amputation, joint fusion , explain: ------------ 
Score:       6a. Left Leg                   6b. Right Leg 
7. Limb Ataxia:  
0 = Absent 
1 = Present in one limb 
2 = Present in two limbs If present, is ataxia in 
Right arm 1 = Yes 2 = No 
Left arm 1 = Yes 2 = No 
Right leg 1 = Yes 2 = No 
Left leg 1 = Yes 2 = No 
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9 = amputation or joint fusion, explain-------------  
Score: 
8. Sensory:  
0 = Normal; no sensory loss. 
1 = Mild to moderate sensory loss; patient feels pinprick is less sharp or is dull 
on the affected side; or there is a loss of superficial pain with pinprick but 
patient is aware he/she is being touched. 
2 = Severe to total sensory loss; patient is not aware of being touched in the 
face, arm, and leg. 
Score: 
9. Best Language:  
0 = No aphasia, normal 
1 = Mild to moderate aphasia; some obvious loss of fluency or facility of 
comprehension, without significant limitation on ideas expressed or form of 
expression. Reduction of speech and/or comprehension, however, makes 
conversation about provided material difficult or impossible. For example, in 
conversation about provided materials, examiner can identify picture or naming 
card from patient’s response. 
2 = Severe aphasia; all communication is through fragmentary expression; great 
need for inference, questioning, and guessing by the listener. Range of 
information that can be exchanged is limited; listener carries burden of 
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communication. Examiner cannot identify materials provided from patient 
response. 
3 = Mute, global aphasia; no usable speech or auditory comprehension. 
Score: 
10. Dysarthria:  
0 = Normal 
1 = Mild to moderate; patient slurs at least some words and, at worst, can be 
understood with some difficulty. 
2 = Severe; patient’s speech is so slurred as to be unintelligible in the absence of 
or out of proportion to any dysphasia, or is mute/anarthric. 
9 = Intubated or other physical barrier, explain--------------------- 
Score: 
11. Extinction and Inattention (formerly Neglect): 
0 = No abnormality. 
1 = Visual, tactile, auditory, spatial, or personal inattention or extinction to 
bilateral simultaneous stimulation in one of the sensory modalities. 
2 = Profound hemi-inattention or hemi-inattention to more than one modality. 
Does not recognize own hand or orients to only one side of space. 
Score: 
TOTAL SCORE(0 to 42):        AT ADMISSION: 
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 >25 Very severe neurological impairment  
 15-24 Severe impairment  
 5-14 Moderately severe impairment  
 <5 Mild impairment  
 (Adams, HP, et al. (1999). Neurology: 53: 126-131) 
MODIFIED RANKIN’S SCALE 
Score 
0= No symptoms at all 
1 =No significant disability despite symptoms; able to carry out all usual duties 
and activities 
2 =Slight disability; unable to carry out all previous activities, but able to look 
after own affairs without assistance 
3 =Moderate disability; requiring some help, but able to walk without assistance 
4 =Moderately severe disability; unable to walk without assistance and unable 
to attend to own bodily needs without assistance 
5 =Severe disability; bedridden, incontinent and requiring constant nursing care 
and attention 
6 =Dead 
TOTAL (0–6):    
     AT ONE MONTH FOLLOW UP: 
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 ABBREVATIONS 
aPTT -  ACTIVATED PARTIAL THROMBOPLASTIN TIME 
ATP -  ADENOSINE TRIPHOSPHATE 
CNS -  CENTRAL NERVOUS SYSTEM 
COX -  CYCLO OXYGENASE 
CRP -  C- REACTIVE PROTEIN 
ELISA-  ENZYME LINKED IMMUNOSORBANT ASSAY  
ESR -  ERYTHROCYTE SEDIMENTATION RATE 
FPA -  FIBRINOPEPTIDE A 
FPB -  FIBRINOPEPTIDE B 
Gp -  GLYCOPROTEIN 
i NOS -  INDUCIBLE NITRIC OXIDE SYNTHASE 
ICAM-1-  INTERCELLULAR ADHESION MOLECULE-1 
ICP -  INTRA CRANIAL PRESSURE 
IHD -  ISCHEMIC HEART DISEASE 
IL-1 -  INTERLEUKIN-1 
IL-6 -  INTERLEUKIN-6 
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LDL -  LOW DENSITY LIPOPROTEIN CHOLESTEROL 
LP(a) -  LIPOPROTEIN a 
MCP-1-  MACOPHAGE CHEMOATTRACTANT PROTEIN-1  
MMP -  MATRIX METALLOPROTEASES 
NH-2  -  AMINO TERMINAL 
PT -  PROTHROMBIN TIME 
PT-Fg -  PROTHROMBIN DERIVED FIBRINOGEN 
PUFA -  POLY UNSATURATED FATTY ACID 
SLE -  SYSTEMIC LUPUS ERYTHEMATOSUS 
SNAP25-  SYNAPTOSOMAL ASSOCIATED PROTEIN 25  
t- PA -  TISSUE PLASMINOGEN ACTIVATOR 
TIA -  TRANSIENT ISCHEMIC ATTACK 
TNF α-  TUMOR NECROSIS FACTOR-α  
TT -  THROMBIN TIME 
VCAM-1-   VASCULAR CELL ADHESION MOLECULE-1  
VEGF -  VASCULAR ENDOTHELIAL GROWTH FACTOR  
WHO -  WORLD HEALTH ORGANISATION 
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